Fig. 5
From: Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer
PFK158 reduces tumor growth in a MYCHigh xenograft model. A H446 xenografts were given 25 mg/kg PFK158 by intraperitoneal injection every other day for 10 days. B PFK158-treated animals exhibited a significant delay in tumor growth. C and D H&E staining showing that PFK158-treated animals have less necrotic tissue. E Immunoblot against MYC and PFKFB3 with loading control Vinculin. F PFKFB3 expression was significantly reduced in H446 tumors from animals treated with PFK158. G and H MYC expression was lower but not significantly so in tumors regardless of PFK158 treatment when evaluated by immunoblotting or flow cytometry, respectively. I Heatmap showing transcriptional expression changes between H446 tumors treated with vehicle or PFK158. J–L SLC2A1, HK2, and PFKFB3 gene expression are not significantly altered following PFK158 treatment. M–O Downstream glycolysis enzyme genes ALDOA, ENO1, and LDHA are significantly lower following PFK158 treatment. (*P < 0.05; ***P < 0.005)